BioArctic

BioArctic Depreciation & Amortization

The Depreciation & Amortization of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 18.43 M SEK. In the previous year, Depreciation & Amortization was 14.63 M SEK — a change of 25.93% (higher).

Depreciation & Amortization

18.43 MSEK

YoY

25.93%

Last updated:

Depreciation & Amortization of BioArctic is 2023 18.43 M SEK. Depreciation & Amortization of BioArctic was 2022 14.63 M SEK. It decreases by 25.93% higher compared to the previous year.

The BioArctic Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2016
1.56 M SEK
Jan 1, 2017
1.99 M SEK
Jan 1, 2018
2.06 M SEK
Jan 1, 2019
9.20 M SEK
Jan 1, 2020
11.01 M SEK
Jan 1, 2021
13.11 M SEK
Jan 1, 2022
14.63 M SEK
Jan 1, 2023
18.43 M SEK
The BioArctic Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
18.43 MSEK+25.93%
14.63 MSEK+11.64%
13.11 MSEK+19.01%
11.01 MSEK+19.72%
9.20 MSEK+346.77%
2.06 MSEK+3.31%
1.99 MSEK+28.08%
1.56 MSEK+1.30%
1.54 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Depreciation & Amortization of BioArctic is 18.43 M SEK in 2023.

Depreciation & Amortization of BioArctic changed from 14.63 M SEK to 18.43 M SEK, representing a 25.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization BioArctic since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BioArctic

All Key Metrics — BioArctic